

16JAN 02

OMB N . 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06478.1463-00000	Serial No.	To Be Assigned 10/046278
Applicant	C. Jane ROBINSON et al.		
Filing Date	Herewith 16JAN 02	Group:	To Be Assigned 1651

U.S. PTO
10/046278
01/16/02

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or N

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
JMO	Abdulkadir, S.A., et al., "Tissue Factor Expression and Angiogenesis in Human Prostate Carcinoma," <i>Human Pathology</i> , 31(4):443-447 (2000).
JMO	Carmeliet, P., "Mechanisms of Angiogenesis and Arteriogenesis," <i>Nature Medicine</i> , 6(3):389-395 (2000).
JMO	Romisch, J., et al., "Antithrombin III Isoform Proportion in Plasmas of Healthy Subjects, Septic Patients and at III Concentrates: A Novel Method of Quantification," Abstract, <i>Intens. Care Med.</i> 2000, 26(3):S303 (2000).
JMO	O'Reilly, M.S., et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin," <i>Science</i> , 285:1926-1928 (1999).
JMO	Vacca, A., et al., "Antiangiogenesis is Produced by Nontoxic Doses of Vinblastine," <i>Blood</i> , 94(12):4143-4155 (1999).
JMO	Witmer, M.R., et al., "Antithrombin III- β Associates more Readily than Antithrombin III- α with Uninjured and De-endothelialized Aortic Wall <i>In Vitro</i> and <i>In Vivo</i> ," <i>Arterioscler. Thromb.</i> , 11(3):530-539 (1991).

Examiner	John L. Abzug	Date Considered	27 Oct 03
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION






06 Feb 03
OMB N. 0651-0011
RECEIVED
O I P E
FEB 12 2003
TECH CENTER 1600/2900
PATENT & TRADEMARK

Atty. Docket No.	06478.1463-00	Application No.	10/046,278
Applicant	C. Jane ROBINSON et al.		
Filing Date	January 16, 2002	Group:	4646 / 651




U.S. PATENT DOCUMENTS


Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or N
	1	WO 00/20026 A2	4/13/2000	PCT	A 61 K	38/55
	2	WO 00/54801 A1	9/21/2000	PCT	A 61 K	38/48
	3	EP 1 075 840 A2	2/14/2001	EPO	A 61 K	38/57 Abstract
	4	WO 02/22150 A2	3/21/2002	PCT	A 61 K	38/00 Abstract
	5	EP 0 438 234 A1	7/24/1991	EPO	A 61 K	37/02

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	6	B. Eisele and M. Lamy, "Clinical Experience with Antithrombin III Concentrates in Critically Ill Patients with Sepsis and Multiple Organ Failure," <i>Seminars in Thrombosis and Hemostasis</i> , 24(1):71-80 (1998).
	7	R. Clemens, et al., "Antithrombin III Substitution Affects Survival Rate in a Murine Malaria Model," <i>Parasitology Research</i> , 76(1):36-38 (1989).
	8	M.S. O'Reilly, et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin," <i>Science</i> , 285(17):1926-1928 (1999).

Examiner		Date Considered	27 Oct 03
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	